0000000000147529

AUTHOR

Giubilato A

showing 8 related works from this author

Effects of Two Different ACE Inhibitors, Captopril and Delapril, in the Early Phases of Acute Anterior Myocardial Infarction

1999

Objective: This study was aimed at investigating the effects of captopril or delapril before and just after thrombolysis in acute anterior myocardial infarction (AMI). Patients and Methods: Study participants consisted of 89 patients, hospitalised within 4 hours of the onset of symptoms. Patients were randomly divided into two groups: the first group (45 patients, pretreatment group) received captopril 6.25mg or delapril 7.5mg orally about 15 minutes before intravenous administration of recombinant tissue plasminogen activator (rt-PA) 100mg; the second group (44 patients, late-treatment group) received captopril or delapril about 4 to 6 hours after thrombolytic treatment. Captopril/delapril…

medicine.medical_specialtyEjection fractionbiologybusiness.industrymedicine.medical_treatmentDelaprilCaptoprilGeneral MedicineThrombolysismedicine.diseaseBlood pressureHeart failureInternal medicinemedicinebiology.proteinCardiologyPharmacology (medical)Creatine kinasecardiovascular diseasesMyocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct

Effects of the Combination of Candesartan plus Captopril in Elderly Patients with Anterior Myocardial Infarction

2000

Objective: To verify the feasibility, tolerability and efficacy of the combination of captopril (75 mg/day) and candesartan (8 mg/day) in early postinfarction phases of not thrombolysed and unreperfused anterior acute myocardial infarction (AMI) in elderly patients. Design and Patients: 71 patients (aged >65 years) hospitalised for anterior AMI were randomised in a double-blind manner into two groups: group A included 35 patients who received captopril 75 mg/day within 3 days of admission plus candesartan 4mg, as a first dose, and 8 mg/day successively; group B included 36 patients who received captopril 75 mg/day and placebo. 90 days after admission, patients underwent echocardiography to …

medicine.medical_specialtyCreatinineEjection fractionbusiness.industryCaptoprilGeneral MedicinePlacebomedicine.diseaseCandesartanchemistry.chemical_compoundBlood pressurechemistryTolerabilityInternal medicineCardiologyMedicinePharmacology (medical)Myocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct

415 Does angiotensin-converting enzyme I/D polymorphism afect blood pressure and diastolic function? Findings after six years of follow up in healthy…

2003

medicine.medical_specialtyBlood pressureAngiotensin converting enzyme ibusiness.industryPolymorphism (computer science)Internal medicinemedicineHealthy subjectsCardiologyDiastolic functionCardiology and Cardiovascular MedicinebusinessEuropean Journal of Heart Failure Supplements
researchProduct

Use of bivalirudin for heparin-induced thrombocytopaenia after thrombolysis in massive pulmonary embolism: a case report

2009

A 68-year-old man was referred to the emergency department 6 h after onset of sudden acute dyspnoea. Immediate ECG showed sinus tachycardia with the typical S1-Q3-T3 pattern and incomplete right bundle branch block. The echocardiogram showed the presence of mobile thrombus in the right atrium, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Lung spiral computed tomography (CT) showed bilateral pulmonary involvement and confirmed the picture of a thrombotic system in the right atrium and caval vein. Thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) and heparin (alteplase 10 mg bolus,…

medicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentCase ReportInternal medicinebivalirudin Heparin-induced thrombocytopaenia Pulmonary embolism ThrombolysismedicineBivalirudinHeparin-induced thrombocytopaeniaInterventricular septumcardiovascular diseasesThrombusLungbusiness.industryPulmonary embolismThrombolysismedicine.diseaseThrombolysisSpiral computed tomographyPulmonary embolismmedicine.anatomical_structureVentricleCardiologycardiovascular systemEmergency MedicinebusinessBivalirudinmedicine.drugInternational Journal of Emergency Medicine
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct

Relationship between ACE-DD polymorphism and diastolic performance in healthy subjects.

2004

Background—The ACE-D allele has been associated with cardiovascular disease. The study evaluates the relationship between the ACE-ID genotypes and diastolic function in healthy subjects after 6 years of follow-up. Methods—Two hundred and seventy-five healthy volunteers aged 25–55 years had normal physical examination, 12-lead ECG, acceptable echocardiographic windows and echocardiogram at entry. Venous blood was drawn for DNA analysis. Results—Two hundred and forty-two subjects completed 6 years of follow-up. Three genetically distinct groups were obtained: ACE-DD group (n=71, 26F/45M, mean age 48±7 years); ACE-ID (n=115, 39F/76M, mean age 40±7 years); and ACE-II (n=56, 20F/36M, mean age 47…

AdultMalemedicine.medical_specialtyTime FactorsGenotypeDiastolePhysical examinationPeptidyl-Dipeptidase ARisk AssessmentWhite PeopleCohort StudiesSex FactorsPolymorphism (computer science)DiastolePredictive Value of TestsReference ValuesInternal medicinemedicineHumansProspective StudiesProspective cohort studyAllelesProbabilityAnalysis of VariancePolymorphism Geneticmedicine.diagnostic_testbusiness.industryAge FactorsHemodynamicsVenous bloodMiddle AgedEchocardiography DopplerSurgeryPredictive value of testsMultivariate AnalysisCardiologyFemaleAnalysis of varianceCardiology and Cardiovascular MedicinebusinessCohort studyFollow-Up StudiesScandinavian cardiovascular journal : SCJ
researchProduct

Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine …

2000

Many authors have reported an association between the angiotensin-converting enzyme (ACE)-D allele and coronary heart disease and other cardiovascular diseases. The mechanism underlying the positive associations between the ACE-D alleles and diseases are not yet clear. Previous reports showed an association between migraine without aura and ACE-D allele polymorphism. The study is aimed to evaluate if the DD genotype could also be associated with the frequency and duration of migraine without aura. In 302 patients suffering from migraine without aura (at least for 1 year), with no history of cardiovascular diseases and major risk factors for ischemic events, the genotypes of the ACE gene, pl…

AdultMalemedicine.medical_specialtyGenotypeAuraMigraine DisordersPeptidyl-Dipeptidase AGastroenterologyCentral nervous system diseasePolymorphism (computer science)Internal medicineGenotypeMedicineHumansAllelesPolymorphism Geneticbiologybusiness.industryVascular diseaseAngiotensin-converting enzymeMiddle Agedmedicine.diseaseEndocrinologyNeurologyMigrainebiology.proteinFemaleNeurology (clinical)Gene polymorphismChromosome DeletionbusinessEuropean neurology
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refr…

2000

Background: Diuretics, have been accepted as first-line treatment in refractory heart failure, but a lack of response is a frequent event. A randomised single blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory NYHA class IV congestive heart failure (CHF). Materials and methods: Sixty patients (21 F/39 M) with refractory CHF (NYHA class IV) of different etiologies, unresponsive to high oral doses of furosemide, ACE-inhibitors, digitalis, and nitrates, aged 65–90 years, were enrolled. They had to have an ejection fraction (EF) < 35%, serum creatinine < 2 mg/dl, B…

Malemedicine.medical_specialtyDiuresisBlood PressurePotassium Chloridechemistry.chemical_compoundBolus (medicine)FurosemideHeart RateHumansMedicineSingle-Blind MethodDiureticsInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicCreatinineEjection fractionbusiness.industryBody WeightSodiumFurosemideMiddle Agedmedicine.diseaseHypokalemiaDiuresisUric AcidSurgerychemistryCreatinineAnesthesiaHeart failurePotassiumDrug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugEuropean Journal of Heart Failure
researchProduct